This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Otsuka Holdings Co., Ltd.

Drug Names(s): OCV-105

Description: OCV-105 is a therapeutic cancer vaccine that targets the tumor specific antigen, which is highly expressed in pancreatic cancer. OCV-105 potentially suppresses the growth and progress of pancreatic cancer by the induction and activation of cytotoxic T-cells which directly damage pancreatic cancer cells.

Deal Structure: OCV-105 has been co-developed by OncoTherapy Science, Inc. and Otsuka Pharmaceutical.

Partners: OncoTherapy Science, Inc.

OCV-105 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug